A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report
The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus doxorubicin as neoadjuvant therapy for stage IIIB breast cancer. Thirty-nine chemotherapy-naive patients were enrolled in the study. The me...
Saved in:
Published in | Seminars in oncology Vol. 28; no. 3 Suppl 10; p. 57 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.06.2001
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus doxorubicin as neoadjuvant therapy for stage IIIB breast cancer. Thirty-nine chemotherapy-naive patients were enrolled in the study. The median age was 54 years (range, 32 to 74 years), and the median Karnofsky performance status was 100. Gemcitabine 1,200 mg/m(2) was given on days 1 and 8, and doxorubicin 60 mg/m(2) on day 1, followed by surgery or radiotherapy. Ninety-seven of 117 cycles (83%) were administered at full dose. An overall response rate of 95% was obtained, with a complete response in 18% (seven patients) and a partial response in 77% (30 patients). Twenty-eight patients (72%) underwent breast surgery after a maximum of three cycles of neoadjuvant therapy. World Health Organization grade 3/4 toxicities included leukopenia in nine cycles (8%), neutropenia in 16 cycles (14%), febrile neutropenia in 11 cycles (9%), and anemia in two cycles (2%). The most important nonhematologic toxicity was grade 2/4 mucositis in 16 cycles (14%), and/or grade 2/3 diarrhea in 10 cycles (9%). Neoadjuvant therapy with gemcitabine plus doxorubicin results in a high tumor response rate with moderate oral and hematologic toxicity. Semin Oncol 28 (suppl 10):57-61. |
---|---|
AbstractList | The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus doxorubicin as neoadjuvant therapy for stage IIIB breast cancer. Thirty-nine chemotherapy-naive patients were enrolled in the study. The median age was 54 years (range, 32 to 74 years), and the median Karnofsky performance status was 100. Gemcitabine 1,200 mg/m(2) was given on days 1 and 8, and doxorubicin 60 mg/m(2) on day 1, followed by surgery or radiotherapy. Ninety-seven of 117 cycles (83%) were administered at full dose. An overall response rate of 95% was obtained, with a complete response in 18% (seven patients) and a partial response in 77% (30 patients). Twenty-eight patients (72%) underwent breast surgery after a maximum of three cycles of neoadjuvant therapy. World Health Organization grade 3/4 toxicities included leukopenia in nine cycles (8%), neutropenia in 16 cycles (14%), febrile neutropenia in 11 cycles (9%), and anemia in two cycles (2%). The most important nonhematologic toxicity was grade 2/4 mucositis in 16 cycles (14%), and/or grade 2/3 diarrhea in 10 cycles (9%). Neoadjuvant therapy with gemcitabine plus doxorubicin results in a high tumor response rate with moderate oral and hematologic toxicity. Semin Oncol 28 (suppl 10):57-61. |
Author | Gomez, H Kahatt, C Vallejos, C de Mendoza, F H Pen, D L Falcon, S Santillana, S Otero, J Valdivia, S |
Author_xml | – sequence: 1 givenname: H surname: Gomez fullname: Gomez, H organization: Department of Medicine, Instituto de Enfermedades Neoplásicas, Avenida Angamos Este 2520, Lima 34, Perú – sequence: 2 givenname: C surname: Kahatt fullname: Kahatt, C – sequence: 3 givenname: S surname: Falcon fullname: Falcon, S – sequence: 4 givenname: S surname: Santillana fullname: Santillana, S – sequence: 5 givenname: F H surname: de Mendoza fullname: de Mendoza, F H – sequence: 6 givenname: S surname: Valdivia fullname: Valdivia, S – sequence: 7 givenname: C surname: Vallejos fullname: Vallejos, C – sequence: 8 givenname: J surname: Otero fullname: Otero, J – sequence: 9 givenname: D L surname: Pen fullname: Pen, D L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/11510035$$D View this record in MEDLINE/PubMed |
BookMark | eNo9j0tLw0AUhWdRsQ_9CcosdRG9M8nNtO5q8REouFDXZR43NaWZhJmJ2H-v4gMOHDjwHc6ZspHvPDF2JuBKgCivnwEWeaYUFhcgLucAAjIcscl_PGbTGHcAUigpj9lYCBQAOU6YX_L-TUfiVcVjGtyBdzX31Gm3G961T3xLrW2SNo0n3u-HyF330YXBNLbx_Esx6e03Xd1yE0jHxK32lsIN17wPtG_axutw4IH6LqQTdlTrfaTTX5-x1_u7l9Vjtn56qFbLdWZzwJQhFkpLVcjSOXKolEDAuUJyAAbzutSwsM6UqGsS1giXF6pcKLS1odqVczlj5z-9_WBacps-NO3Xis3fcfkJ9ytcOg |
CitedBy_id | crossref_primary_10_1007_s12094_007_0059_7 crossref_primary_10_1093_annonc_mdj973 crossref_primary_10_1007_s12282_012_0343_4 crossref_primary_10_1038_sj_bjc_6604322 crossref_primary_10_3816_CBC_2002_s_007 crossref_primary_10_1016_j_breast_2005_11_010 crossref_primary_10_3816_CBC_2002_s_009 crossref_primary_10_1007_s10549_004_1003_y crossref_primary_10_3816_CBC_2004_s_006 |
ContentType | Journal Article |
Copyright | Copyright 2001 by W.B. Saunders Company. |
Copyright_xml | – notice: Copyright 2001 by W.B. Saunders Company. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/S0093-7754(01)80010-5 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 11510035 |
Genre | Multicenter Study Clinical Trial, Phase II Clinical Trial Journal Article |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1P~ 3O- 4.4 457 4CK 53G 5RE AAEDW AALRI AAQOH AAQQT AAQXK AAWTL AAXUO ABFRF ABJNI ABOCM ABUDA ACGFO ADBBV ADMUD AEFWE AENEX AEVXI AFCTW AFETI AFFNX AFJKZ AFRHN AFTJW AGHFR AGRDE AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IH2 J5H K-O L7B MJL N4W NPM O9- OC~ OO- P2P R2- RIG ROL SEL SES SJN TWZ UDS X7M Z5R ZGI ZXP |
ID | FETCH-LOGICAL-c305t-5547a27426dded5771505875ed00b53f6a09cdb65afe1cb1d3476975cfbefd682 |
ISSN | 0093-7754 |
IngestDate | Sat Sep 28 07:35:21 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 Suppl 10 |
Language | English |
License | Copyright 2001 by W.B. Saunders Company. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c305t-5547a27426dded5771505875ed00b53f6a09cdb65afe1cb1d3476975cfbefd682 |
PMID | 11510035 |
ParticipantIDs | pubmed_primary_11510035 |
PublicationCentury | 2000 |
PublicationDate | 2001-Jun |
PublicationDateYYYYMMDD | 2001-06-01 |
PublicationDate_xml | – month: 06 year: 2001 text: 2001-Jun |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Seminars in oncology |
PublicationTitleAlternate | Semin Oncol |
PublicationYear | 2001 |
SSID | ssj0021722 |
Score | 1.7323205 |
Snippet | The purpose of this ongoing study is to determine the response and safety of a combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN)... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 57 |
SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Doxorubicin - administration & dosage Female Humans Middle Aged Neoadjuvant Therapy |
Title | A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11510035 |
Volume | 28 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2RUJcqpZneckHDqAokKez4bZUlAZEL9tKvVUe22mFukm0ZCXgV_CTmbGzu94C4iFFURQrluX5Mp73MPasLJWKAepQySwLMyPysIREh0WupBImrjNpo3yPxdFp9v4sPxuNvntRS4seXqpvv8wr-R-q4jukK2XJ_gNlV5PiC3xG-uIdKYz3v6LxJOgu8RQKqsqVibVRGaaV-tMCBeQ-uDAzhbo_kCTZXS0-B7r90s4XQN50MnSgZHhBX1dvAqDg9J5iwJSZuwzobm6ubM-v-dfBteBLslNjh2w4bduoDev8u3bmDNMrP9QHeSmdG2pllT2U5AvbsL5OcdHUBcnlqU03LBJe5NSSy5ZpSJX1fC6bjD00pYHtWRoMEa2Od7pC1T-xdGddmK4mRcGbmguUY1Jnw9z_Bnenm1lao5wbk5P0z6PXqm0vh7bYVjEmjnlM1p9BgY-HwprLpawzwl6t1_c8il8Ma6OKtMN817QWK72c7LKdQe3gE4ehPTYyzW128-MQWHGHNRNuocSrilso8bbmHpS4ByVOUOIelDheFkqcoMQdlLiD0msuuQck7oB0l50evj05OAqHVhyhwgOhD1HoLCR59QUehzovCtQjclR1jY4iyNNayKhUGkQuaxMriHWaFaLEH74GU2sxTu6x7aZtzAPGI5NAAkUMOtGZSBVIAFAlCmvK5LXI9tl9t1Pnnau3cr7cw4e_HXnEbq2B-JjdqPEHN09QWuzhqSXhD6BbZp0 |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+II+study+of+neoadjuvant+gemcitabine+plus+doxorubicin+in+stage+IIIB+breast+cancer%3A+a+preliminary+report&rft.jtitle=Seminars+in+oncology&rft.au=Gomez%2C+H&rft.au=Kahatt%2C+C&rft.au=Falcon%2C+S&rft.au=Santillana%2C+S&rft.date=2001-06-01&rft.issn=0093-7754&rft.volume=28&rft.issue=3+Suppl+10&rft.spage=57&rft_id=info:doi/10.1016%2FS0093-7754%2801%2980010-5&rft_id=info%3Apmid%2F11510035&rft_id=info%3Apmid%2F11510035&rft.externalDocID=11510035 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0093-7754&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0093-7754&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0093-7754&client=summon |